These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7858)

  • 1. [Clinical pharmacology of the beta-adrenolytic activity of pindolol].
    Hugues FC; Julien D; Munera Y; Heams D; Marche J
    Therapie; 1976; 31(2):179-93. PubMed ID: 7858
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemodynamic characterization of a new beta-receptor blocker: mepindolol at rest, during ergometer exercise and in the isoproterenol study in comparison with practolol and pindolol.
    Boneli J
    Int J Clin Pharmacol Biopharm; 1977 Jul; 15(7):325-31. PubMed ID: 19363
    [No Abstract]   [Full Text] [Related]  

  • 3. [Beta adrenolytic activity and hemodynamic effects of penbutolol].
    Boissier JR; Coutte R; Advenier C; Giudicelli JF
    Therapie; 1973; 28(6):1251-65. PubMed ID: 4152643
    [No Abstract]   [Full Text] [Related]  

  • 4. Adrenergic beta-receptor blockade in essential hypertension: a comparison between pindolol (Visken) and propranolol (Inderal).
    Bjerle P; Jacobsson KA; Agert G
    Curr Ther Res Clin Exp; 1975 Sep; 18(3):387-94. PubMed ID: 241607
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hemodynamic effects of intravenous injection of beta-adrenergic inhibitor (Pindolol) in man].
    Scebat L; Rocha P; Ourbak P; Renais J; Lenègre J
    G Ital Cardiol; 1972; 2(5):626-35. PubMed ID: 4404052
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hypertension with a new beta-adrenergic blocking agent, pindolol (Viskén)].
    Persson I; Ulrich J
    Ugeskr Laeger; 1973 May; 135(20):968-70. PubMed ID: 4755952
    [No Abstract]   [Full Text] [Related]  

  • 8. [Utilization of pindolol in arterial hypertension. Study during rest and during effort].
    Tassy J; Jouve A
    Nouv Presse Med; 1978 Sep; 7(31):2783-4. PubMed ID: 30964
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta-blocking potency of mepindolol and pindolol against isoproterenol-induced inotropic and chronotropic responses in guinea pig atria.
    Anderson WG
    J Cardiovasc Pharmacol; 1984; 6(1):7-11. PubMed ID: 6199615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoprenaline antagonism and duration of action in exercise induced tachycardia of three -adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol.
    Aellig WH
    Br J Pharmacol; 1973 Mar; 47(3):621P-622P. PubMed ID: 4147193
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of essential hypertension with pindolol and clopamide: problems arising from a combined beta blocker and diuretic therapy.
    Rosenfeld JB; Traub YM; Cohen L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):786-97. PubMed ID: 4217245
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative pharmacological studies on beta-adrenolytic agents. An analysis of quantitative activity (author's transl)].
    Zechel HJ
    Arzneimittelforschung; 1977; 27(5):991-9. PubMed ID: 18159
    [No Abstract]   [Full Text] [Related]  

  • 13. [Study of pindolol given once daily in a dose of 15 mg in arterial hypertension].
    Barraine R; Bouchez C
    Nouv Presse Med; 1978 Sep; 7(31):2765-6. PubMed ID: 30959
    [No Abstract]   [Full Text] [Related]  

  • 14. [Data from the study of effort blood pressure profile in hypertensive subjects, before and after treatment].
    Debru JL; Doyon B; Morin B; Perdrix A; Mallion JM
    Nouv Presse Med; 1978 Sep; 7(31):2777-82. PubMed ID: 30963
    [No Abstract]   [Full Text] [Related]  

  • 15. [Action of various beta adrenolytic agents on the alpha blocking properties of yohimbine in the dog].
    Mouillé P; Cheymol G
    C R Seances Soc Biol Fil; 1973; 167(3):440-2. PubMed ID: 4150410
    [No Abstract]   [Full Text] [Related]  

  • 16. [Value of a single oral dose of pindolol].
    Safar M; Weiss Y; Milliez P
    Nouv Presse Med; 1978 Sep; 7(31):2767-8. PubMed ID: 30960
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.
    Ishibashi T; Mitomi A; Tatebe S; Imai S
    Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects on renin release of beta adrenergic antagonists with differing properties.
    Weber MA; Stokes GS; Gain JM
    J Clin Invest; 1974 Dec; 54(6):1413-9. PubMed ID: 4154950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemodynamic long-term effects of a beta-receptor blockader (Pindolol) in primary essential hypertension].
    Klein WW; Brandt D; Fluch N; Goebel R; Holzer H; Pöch G
    Adv Clin Pharmacol; 1976; 11():79-85. PubMed ID: 1032573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy with hydrazinopyridazine, a new antihypertensive vasodilatory agent, in combination with beta-receptor blocking substances.
    Kirch W; von Gizycki C
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):233-5. PubMed ID: 6104636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.